The ATDC Conference has been an integral part of education and case-based study of upcoming and new diabetes technology for over 25 years. This is an annual course designed to help healthcare providers caring for patients with diabetes, including but not limited to: endocrinologists/diabetes specialists, internists, pediatricians, family physicians, physician assistants, medical residents and fellows, nurse practitioners, nurses, dietitians, social workers, and Certified Diabetes Care and Education Specialists (CDCES).
Attendees will have an opportunity to interact with leaders in the field and participate in detailed question and answer sessions with the experts. The 2023 ATDC Conference will address the following needs: improving glucose control; overweight and obesity epidemic; managing diabetes in special circumstances (toddlers, elderly, etc.); therapy options based on new data to prevent and/or treat cardiovascular, kidney, and eye disease; ever-increasing healthcare costs, especially in the hospital system; emerging technologies for artificial pancreas (Hybrid Closed-Loop systems), continuous glucose managing (CGM) systems, and other insulin-delivery systems; the emerging role of Time-In-Range (TIR), Time-In-Tight-Range (TITR), and other CGM metrics for day-to-day diabetes management; effective management of glucose control before, during, and post-pregnancy associated with T1D; real-life clinical challenges in hypoglycemia management; nutritional and diabetes management; clinical challenges in both pediatric and adult care; and COVID-19 diabetes management, specifically integrating telemedicine in clinical care. Finally, we will host 6 keynotes to touch on a wide range of topics.
- Evaluate the implementation of CGMs in different settings (ie: achieve tight glucose control (TITR) during pregnancy or inpatient);
- Compare the appropriate therapeutic choices for both eye and kidney disease in patients with diabetes;
- Summarize poor outcomes related to glucose control and additional risk factors for co-morbidities in overweight and obese patients;
- Interpret better CGM data and different metrics to improve diabetes outcomes instead of HbA1c alone;
- Contract different AID and/or HCL systems for people with T1D and insulin-requiring patients with T2D.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Colorado School of Medicine and Barbara Davis Center for Diabetes. The University of Colorado School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Colorado School of Medicine designates this live activity for a maximum of 27.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For more information please visit the official event page.